TCGA-C8-A1HJ-01A-11R-A13Q-07
— · E
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- E
- subtype
- E
- overall_survival_months
- 0
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.630
- MYC_TARGETS_V1+0.600
- MYC_TARGETS_V2+0.590
- G2M_CHECKPOINT+0.540
- MTORC1_SIGNALING+0.360
- SPERMATOGENESIS+0.340
- PANCREAS_BETA_CELLS+0.190
- NOTCH_SIGNALING+0.140
- HEDGEHOG_SIGNALING+0.130
- DNA_REPAIR+0.120
Top 10 suppressed
- ESTROGEN_RESPONSE_EARLY-0.400
- MYOGENESIS-0.330
- INTERFERON_ALPHA_RESPONSE-0.320
- APICAL_SURFACE-0.250
- APICAL_JUNCTION-0.240
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.240
- XENOBIOTIC_METABOLISM-0.240
- BILE_ACID_METABOLISM-0.230
- P53_PATHWAY-0.220
- ESTROGEN_RESPONSE_LATE-0.200
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-AN-A0AT-01A-11R-A034-07 | — | E | 0.843 |
| 2 | TCGA-E9-A22G-01A-11R-A157-07 | — | E | 0.827 |
| 3 | SRR29022831 | — | E | 0.823 |
| 4 | TCGA-A2-A04T-01A-21R-A034-07 | — | E | 0.821 |
| 5 | BS_W644VEVE | Med | Medulloblastoma | 0.819 |
| 6 | SRR8518152 | — | E | 0.818 |
| 7 | BS_9NZ2D6AD | Med | Medulloblastoma | 0.815 |
| 8 | SRR10900561 | — | — | 0.813 |
| 9 | 20040122.TNBC | — | E | 0.811 |
| 10 | SRR25617937 | — | E | 0.806 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 21 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.630 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.600 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.590 | Idelalisib | — uncovered |
| G2M_CHECKPOINT | 0.540 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.360 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.340 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.190 | Cobimetinib | — uncovered |
| NOTCH_SIGNALING | 0.140 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.130 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.120 | Idelalisib | — uncovered |
| KRAS_SIGNALING_DN | 0.110 | Remibrutinib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.100 | Remibrutinib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.100 | Idelalisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.090 | Remibrutinib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.070 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.050 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.040 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.020 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.020 | Idelalisib | — uncovered |
| ANDROGEN_RESPONSE | 0.010 | Inavolisib | — uncovered |